Natural immunity to grafts of FLD-3 erythroleukemia cells by irradiated mice.
Mice were irradiated and infused with BALB/c Friend virus-induced FLD-3 erythroleukemia cells. Growth of the cells was estimated by measuring splenic incorporation of 5-iodo-2'-deoxyuridine-125I 5 days after cell transfer. BALB/cJ and C3H mice were 'poor responders' in that FLD-3 cells grew well in their spleens, while mice of other strains were 'good responders', resisting the growth of FLD-3 cells. No H-2 or Fv genetic locus was associated with resistance. Athymic nude mice and mice depleted of marrow tissue by 89Sr or estradiol resisted FLD-3 cells, indicating that the effectors were thymus- and marrow-independent. Silica, carrageenan and Propionibacterium acnes organisms all altered resistance, suggesting a function of macrophages. Neither interferon nor anti-interferon serum treatment altered resistance. Anti-asialo GM1 serum inhibited resistance to FLD-3 cells in vivo and inhibited natural cytotoxic (NC) activity against FLD-3 cells in vitro. NC (FLD-3) activity was greatly decreased in spleens 3 days after irradiation, in contrast with NK (YAC-1) and NC(WEHI-164.1) activities. Moreover, a 3-day delay in infusion of FLD-3 cells 'synergized' with silica in weakening genetic resistance in vivo. Thus, natural immunity to FLD-3 cells in vivo differs from that of genetic resistance to normal bone marrow cell allografts, and the lysis of FLD-3 cells in vitro seems to be mediated by cells which do not easily fit into the definition of natural killer (NK) or natural cytotoxic (NC) cells.
D000818:Animals; D000906:Antibodies; D001212:Asialoglycoproteins / Q000276:immunology; D001853:Bone Marrow / Q000528:radiation effects; D001854:Bone Marrow Cells; D002351:Carrageenan / Q000494:pharmacology; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005622:Friend murine leukemia virus; D005677:G(M1) Ganglioside; D006028:Glycosphingolipids / Q000276:immunology; D007113:Immunity, Innate / Q000528:radiation effects*; D007116:Immunization, Passive; D007372:Interferons / Q000276:immunology / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D004915:Leukemia, Erythroblastic, Acute / Q000097:blood / Q000276:immunology*; D007942:Leukemia, Experimental / Q000276:immunology*; D008168:Lung / Q000166:cytology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C / Q000145:classification; D008815:Mice, Inbred Strains / Q000097:blood / Q000235:genetics; D012822:Silicon Dioxide / Q000494:pharmacology; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D013950:Thymus Gland / Q000166:cytology / Q000276:immunology
D000906:Antibodies; D001212:Asialoglycoproteins; D006028:Glycosphingolipids; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D012822:Silicon Dioxide; D002351:Carrageenan; D007372:Interferons